Determinants of bone marrow adiposity: The modulation of peroxisome proliferator-activated receptor-γ2 activity as a central mechanism

Bone

Volumn 56, Issue 2, 2013, Pages 255-265

  Sadie Van Gijsen, H ^a   Hough, F S ^a   Ferris, W F ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Adipocytes; Bone mineral density; Marrow adiposity; Osteoblasts; PPAR 2

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BISPHOSPHONIC ACID DERIVATIVE; ENDOCANNABINOID; ESTROGEN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 21; GLITAZONE DERIVATIVE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PHYTOESTROGEN; PIOGLITAZONE; RESVERATROL; RISEDRONIC ACID; ROSIGLITAZONE; STRONTIUM RANELATE; VASCULOTROPIN;

ADIPOCYTE; ADIPOGENESIS; AGING; ANOREXIA NERVOSA; BONE DENSITY; BONE MARROW; BONE MARROW ADIPOSITY; BONE MARROW DEPRESSION; CALORIC RESTRICTION; CARDIOTOXICITY; CELL DIFFERENTIATION; CELL FUNCTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; GENETIC MANIPULATION; GENETIC TRANSCRIPTION; HUMAN; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIPID STORAGE; MECHANICAL STRESS; MESENCHYMAL STEM CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOBLAST; OSTEOPOROSIS; OXIDATIVE STRESS; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW;

ADIPOCYTES; BONE MINERAL DENSITY; MARROW ADIPOSITY; OSTEOBLASTS; PPAR-Γ2;

ADIPOSITY; ANIMALS; BONE MARROW; HUMANS; PPAR GAMMA;

EID: 84880346635     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.06.016     Document Type: Review

References (242)

1. Nuttall M.E., Gimble J.M. Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 2004, 4:290-294.
2. Gimble J.M., Zvonic S., Floyd Z.E., Kassem M., Nuttall M.E. Playing with bone and fat. J Cell Biochem 2006, 98:251-266.
3. Justesen J., Stenderup K., Ebbesen E.N., Mosekilde L., Steiniche T., Kassem M. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2001, 2:165-171.
4. Verma S., Rajaratnam J.H., Denton J., Hoyland J.A., Byers R.J. Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J Clin Pathol 2002, 55:693-698.
5. Shen W., Chen J., Punyanitya M., Shapses S., Heshka S., Heymsfield S.B. MRI-measured bone marrow adipose tissue is inversely related to DXA-measured bone mineral in Caucasian women. Osteoporos Int 2007, 18:641-647.
6. Di Iorgi N., Rosol M., Mittelman S.D., Gilsanz V. Reciprocal relation between marrow adiposity and the amount of bone in the axial and appendicular skeleton of young adults. J Clin Endocrinol Metab 2008, 93:2281-2286.
7. Di Iorgi N., Mo A.O., Grimm K., Wren T.A., Dorey F., Gilsanz V. Bone acquisition in healthy young females is reciprocally related to marrow adiposity. J Clin Endocrinol Metab 2010, 95:2977-2982.
8. Wren T.A., Chung S.A., Dorey F.J., Bluml S., Adams G.B., Gilsanz V. Bone marrow fat is inversely correlated to cortical bone in young and old subjects. J Clin Endocrinol Metab 2011, 96:782-786.
9. Bredella M.A., Torriani M., Ghomi R.H., Thomas B.J., Brick D.J., Gerweck A.V., et al. Vertebral bone marrow fat is positively associated with visceral fat and inversely associated with IGF-1 in obese women. Obesity (Silver Spring) 2011, 19:49-53.
10. Shen W., Scherzer R., Gantz M., Chen J., Punyanitya M., Lewis C.E., et al. Relationship between MRI-measured bone marrow adipose tissue and hip and spine bone mineral density in African-American and Caucasian participants: the CARDIA study. J Clin Endocrinol Metab 2012, 97:1337-1346.
11. Song L., Tuan R.S. Transdifferentiation potential of human mesenchymal stem cells derived from bone marrow. FASEB J 2004, 18:980-982.
12. Moore S.G., Dawson K.L. Red and yellow marrow in the femur: age-related changes in appearance at MR imaging. Radiology 1990, 175:219-223.
13. Kugel H., Jung C., Schulte O., Heindel W. Age- and sex-specific differences in the 1H-spectrum of vertebral bone marrow. J Magn Reson Imaging 2001, 13:263-268.
14. Liney G.P., Bernard C.P., Manton D.J., Turnbull L.W., Langton C.M. Age, gender, and skeletal variation in bone marrow composition: a preliminary study at 3.0 Tesla. J Magn Reson Imaging 2007, 26:787-793.
15. De Bisschop E., Luypaert R., Louis O., Osteaux M. Fat fraction of lumbar bone marrow using in vivo proton nuclear magnetic resonance spectroscopy. Bone 1993, 14:133-136.
16. Griffith J.F., Yeung D.K., Ma H.T., Leung J.C., Kwok T.C., Leung P.C. Bone marrow fat content in the elderly: a reversal of sex difference seen in younger subjects. J Magn Reson Imaging 2012, 36:225-230.
17. Rozman C., Feliu E., Berga L., Reverter J.C., Climent C., Ferrán M.J. Age-related variations of fat tissue fraction in normal human bone marrow depend both on size and number of adipocytes: a stereological study. Exp Hematol 1989, 17:34-37.
18. Ecklund K., Vajapeyam S., Feldman H.A., Buzney C.D., Mulkern R.V., Kleinman P.K., et al. Bone marrow changes in adolescent girls with anorexia nervosa. J Bone Miner Res 2010, 25:298-304.
19. Devlin M.J., Cloutier A.M., Thomas N.A., Panus D.A., Lotinun S., Pinz I., et al. Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. J Bone Miner Res 2010, 25:2078-2088.
20. Wajchenberg B.L., Bosco A., Marone M.M., Levin S., Rocha M., Lerário A.C., et al. Estimation of body fat and lean tissue distribution by dual energy x-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease. J Clin Endocrinol Metab 1995, 80:2791-2794.
21. Björntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord 1996, 20:291-302.
22. Vande Berg B.C., Malghem J., Lecouvet F.E., Devogelaer J.P., Maldague B., Houssiau F.A. Fat conversion of femoral marrow in glucocorticoid-treated patients: a cross-sectional and longitudinal study with magnetic resonance imaging. Arthritis Rheum 1999, 42:1405-1411.
23. Baum T., Yap S.P., Karampinos D.C., Nardo L., Kuo D., Burghardt A.J., et al. Does vertebral bone marrow fat content correlate with abdominal adipose tissue, lumbar spine bone mineral density, and blood biomarkers in women with type 2 diabetes mellitus?. J Magn Reson Imaging 2012, 35:117-124.
24. Geer E.B., Shen W., Strohmayer E., Post K.D., Freda P.U. Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI. J Clin Endocrinol Metab 2012, 97:1702-1711.
25. Gimble J.M., Robinson C.E., Wu X., Kelly K.A. The function of adipocytes in the bone marrow stroma: an update. Bone 1996, 19:421-428.
26. Rosen C.J., Bouxsein M.L. Mechanisms of disease: is osteoporosis the obesity of bone?. Nat Clin Pract Rheumatol 2006, 2:35-43.
27. Lecka-Czernik B. Marrow fat metabolism is linked to the systemic energy metabolism. Bone 2012, 50:534-539.
28. Kawai M., Rosen C.J. PPARgamma: a circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol 2010, 6:629-636.
29. Krings A., Rahman S., Huang S., Lu Y., Czernik P.J., Lecka-Czernik B. Bone marrow fat has brown adipose tissue characteristics, which are attenuated with aging and diabetes. Bone 2012, 50:546-552.
30. Tran M.A., Dang T.L., Berlan M. Effects of catecholamines on free fatty acid release from bone marrow adipose tissue. J Lipid Res 1981, 22:1271-1276.
31. Lecka-Czernik B. PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism. Curr Osteoporos Rep 2010, 8:84-90.
32. Sadie-Van Gijsen H., Crowther N.J., Hough F.S., Ferris W.F. The interrelationship between bone and fat: from cellular see-saw to endocrine reciprocity. Cell Mol Life Sci 2013, 70:2331-2349.
33. Elbaz A., Wu X., Rivas D., Gimble J.M., Duque G. Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med 2010, 14:982-991.
34. Hozumi A., Osaki M., Goto H., Sakamoto K., Inokuchi S., Shindo H. Bone marrow adipocytes support dexamethasone-induced osteoclast differentiation. Biochem Biophys Res Commun 2009, 382:780-784.
35. Uckan D., Kilic E., Sharafi P., Kazik M., Kaya F., Erdemli E., et al. Adipocyte differentiation defect in mesenchymal stromal cell of patients with malignant infantile osteopetrosis. Cytotherapy 2009, 11:392-402.
36. Naveiras O., Nardi V., Wenzel P.L., Hauschka P.V., Fahey F., Daley G.Q. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature 2009, 460:259-263.
37. Nishikawa M., Ozawa K., Tojo A., Yoshikubo T., Okano A., Tani K., et al. Changes in hematopoiesis-supporting ability of C3H10T1/2 mouse embryo fibroblasts during differentiation. Blood 1993, 81:1184-1192.
38. Belaid-Choucair Z., Lepelletier Y., Poncin G., Thiry A., Humblet C., Maachi M., et al. Human bone marrow adipocytes block granulopoiesis through neurolipin-1-induced granulocyte colony-stimulating factor inhibition. Stem Cells 2008, 26:1556-1564.
39. Yan Q.W., Yang Q., Mody N., Graham T.E., Hsu C.H., Xu Z., et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 2007, 56:2533-2540.
40. Miharada K., Hiroyama T., Sido K., Danjo I., Nagasawa T., Nakamura Y. Lipocalin 2-mediated growth suppression is evident in human erythroid and monocyte/macrophage lineage cells. J Cell Physiol 2008, 215:526-537.
41. Kern P.A., Saghizadeh M., Ong J.M., Bosch R.J., Deem R., Simsolo R.B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995, 95:2111-2119.
42. Zhang Y., Harada A., Bluethmann H., Wang J.B., Nakao S., Mukaida N., et al. Tumor necrosis factor (TNF) is a physiologic regulator of hematopoietic progenitor cells: increase of early hematopoeitic progenitors in TNF receptor p55-deficient mice in vivo and potent inhibition of progenitor cell proliferation by TNF alpha in vitro. Blood 1995, 86:2930-2937.
43. Yokota T., Orotani K., Takahashi I., Ishikawa J., Matsuyama A., Ouchi N., et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000, 96:1723-1732.
44. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
45. Hodgkinson T., Yuan X.F., Bayat A. Adult stem cells in tissue engineering. Expert Rev Med Devices 2009, 6:621-640.
46. Lecka-Czernik B., Suva L.J. Resolving the two "bony" faces of PPAR-gamma. PPAR Res 2006, 2006:27489.
47. Hasegawa T., Oizumi K., Yoshiko Y., Tanne K., Maeda N., Aubin J.E. The PPARgamma-selective ligand BRL-49653 differentially regulates the fate choices of rat calvaria versus rat bone marrow stromal cell populations. BMC Dev Biol 2008, 8:71.
48. Fretz J.A., Nelson T., Xi Y., Adams D.J., Rosen C.J., Horowitz M.C. Altered metabolism and lipodystrophy in the early B-cell factor 1-deficient mouse. Endocrinology 2010, 151:1611-1621.
49. Huang S., Kaw M., Harris M.T., Ebraheim N., McInerney M.F., Najjar S.M., et al. Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1. Bone 2010, 46:1138-1145.
50. Duque G., Li W., Vidal C., Bermeo S., Rivas D., Henderson J. Pharmacological inhibition of PPARγ increases osteoblastogenesis and bone mass in male C57BL/6 mice. J Bone Miner Res 2013, 28:639-648.
51. Tontonoz P., Spiegelman B.M. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008, 77:289-312.
52. Zhu Y., Qi C., Korenberg J.R., Chen X.N., Noya D., Rao M.S., et al. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci U S A 1995, 92:7921-7925.
53. Fajas L., Auboeuf D., Raspe E., Schoonjans K., Lefebvre A.M., Saladin R., et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997, 272:18779-18789.
54. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994, 8:1224-1234.
55. Shockley K.R., Lazarenko O.P., Czernik P.J., Rosen C.J., Churchill G.A., Lecka-Czernik B. PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 2009, 106:232-246.
56. Akune T., Ohba S., Kamekura S., Yamaguchi M., Chung U.I., Kubota N., et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004, 113:846-855.
57. Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994, 79:1147-1156.
58. Zhu H., Miosge N., Schulz J., Schliephake H. Regulation of multilineage gene expression and apoptosis during in vitro expansion of human bone marrow stromal cells with different cell culture media. Cells Tissues Organs 2010, 192:211-220.
59. Yu W.H., Li F.G., Chen X.Y., Li J.T., Wu Y.H., Huang L.H., et al. PPARγ suppression inhibits adipogenesis but does not promote osteogenesis of human mesenchymal stem cells. Int J Biochem Cell Biol 2012, 44:377-384.
60. Sadie-Van Gijsen H., Crowther N.J., Hough F.S., Ferris W.F. Depot-specific differences in the insulin response of adipose-derived stromal cells. Mol Cell Endocrinol 2010, 328:22-27.
61. Berger J., Patel H.V., Woods J., Hayes N.S., Parent S.A., Clemas J., et al. A PPARgamma mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus. Mol Cell Endocrinol 2000, 162:57-67.
62. Burgermeister E., Chuderland D., Hanoch T., Meyer M., Liscovitch M., Seger R. Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. Mol Cell Biol 2007, 27:803-817.
63. Tontonoz P., Graves R.A., Budavari A.I., Erdjument-Bromage H., Lui M., et al. Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. Nucleic Acids Res 1994, 22:5628-5634.
64. Piters E., Boudin E., Van Hul W. Wnt signaling: a win for bone. Arch Biochem Biophys 2008, 473:112-116.
65. Westendorf J.J., Kahler R.A., Schroeder T.M. Wnt signaling in osteoblasts and bone diseases. Gene 2004, 341:19-39.
66. Bennett C.N., Longo K.A., Wright W.S., Suva L.J., Lane T.F., Hankenson K.D., et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A 2005, 102:3324-3329.
67. Jackson A., Vayssiere B., Garcia T., Newell W., Baron R., Roman-Roman S., et al. Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone 2005, 36:585-598.
68. Moldes M., Zuo Y., Morrison R.F., Silva D., Park B.H., Liu J., et al. Peroxisome-proliferator-activated receptor gamma suppresses Wnt/beta-catenin signalling during adipogenesis. Biochem J 2003, 376:607-613.
69. Floyd Z.E., Stephens J.M. Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARγ. Biochim Biophys Acta 2012, 1822:1090-1095.
70. Takada I., Mihara M., Suzawa M., Ohtake F., Kobayashi S., Igarashi M., et al. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat Cell Biol 2007, 9:1273-1285.
71. Hong J.-H., Yaffe M.B. TAZ: a beta-catenin-like molecule that regulates mesenchymal stem cell differentiation. Cell Cycle 2006, 5:176-179.
72. Ichida F., Nishimura R., Hata K., Matsubara T., Ikeda F., Hisada K., et al. Reciprocal roles of MSX2 in regulation of osteoblast and adipocyte differentiation. J Biol Chem 2004, 279:34015-34022.
73. Cheng S.L., Shao J.S., Charlton-Kachigian N., Loewy A.P., Towler D.A. MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem 2003, 278:45969-45977.
74. Lecka-Czernik B., Gubrij I., Moerman E.J., Kajkenova O., Lipschitz D.A., Manolagas S.C., et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 1999, 74:357-371.
75. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000, 21:115-137.
76. Duque G. Bone and fat connection in aging bone. Curr Opin Rheumatol 2008, 20:429-434.
77. Griffith J.F., Yeung D.K., Antonio G.E., Lee F.K., Hong A.W., Wong S.Y., et al. Vertebral bone mineral density, marrow perfusion, and fat content in healthy men and men with osteoporosis: dynamic contrast-enhanced MR imaging and MR spectroscopy. Radiology 2005, 236:945-951.
78. Syed F.A., Oursler M.J., Hefferanm T.E., Peterson J.M., Riggs B.L., Khosla S. Effects of estrogen therapy on bone marrow adipocytes in post-menopausal osteoporotic women. Osteoporos Int 2008, 19:1323-1330.
79. Kajkenova O., Lecka-Czernik B., Gubrij I., Hauser S.P., Takahashi K., Parfitt A.M., et al. Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J Bone Miner Res 1997, 12:1772-1779.
80. D'Ippolito G., Schiller P.C., Ricordi C., Roos B.A., Howard G.A. Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. J Bone Miner Res 1999, 14:1115-1122.
81. Mueller S.M., Glowacki J. Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. J Cell Biochem 2001, 82:583-590.
82. Moerman E.J., Teng K., Lipschitz D.A., Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γ2 transcription factor and TGF-ß/BMP signaling pathway. Aging Cell 2004, 3:379-389.
83. Justesen J., Stenderup K., Eriksen E.F., Kassem M. Maintenance of osteoblastic and adipocytic differentiation potential with age and osteoporosis in human marrow stromal cell cultures. Calcif Tissue Int 2002, 71:36-44.
84. Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of aging. Nature 2000, 408:239-247.
85. Mody N., Parhami F., Sarafian T.A., Demer L.L. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med 2001, 31:509-519.
86. Parhami F., Jackson S.M., Tintut Y., Le V., Balucan J.P., Territo M., et al. Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells. J Bone Miner Res 1999, 14:2067-2078.
87. Huang J.T., Welch J.S., Ricote M., Binder C.J., Willson T.M., Kelly C., et al. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999, 400:378-382.
88. Almeida M., Ambrogini E., Han L., Manolagas S.C., Jilka R.L. Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-γ expression, and diminished pro-osteogenic Wnt signalling in the skeleton. J Biol Chem 2009, 284:27438-27448.
89. Nishikawa K., Nakashima T., Takeda S., Isogai M., Hamada M., Kimura A., et al. Maf promotes osteoblast differentiation in mice by mediating the age-related switch in mesenchymal cell differentiation. J Clin Invest 2010, 120:3455-3465.
90. Serria M.S., Ikeda H., Omoteyama K., Hirokawa J., Nishi S., Sakai M. Regulation and differential expression of the c-maf gene in differentiating cultured cells. Biochem Biophys Res Commun 2003, 310:318-326.
91. Almeida M., Han L., Martin-Millan M., Plotkin L.I., Stewart S.A., Roberson P.K., et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 2007, 282:27285-27297.
92. Shouhed D., Kha H.T., Richardson J.A., Amantea C.M., Hahn T.J., Parhami F. Osteogenic oxysterols inhibit the adverse effects of oxidative stress on osteogenic differentiation of marrow stromal cells. J Cell Biochem 2005, 95:1276-1283.
93. Kim W.K., Meliton V., Amantea C.M., Hahn T.J., Parhami F. 20(S)-hydroxycholesterol inhibits PPARgamma expression and adipogenic differentiation of bone marrow stromal cells through a hedgehog-dependent mechanism. J Bone Miner Res 2007, 22:1711-1719.
94. Kim W.K., Meliton V., Bourquard N., Hahn T.J., Parhami F. Hedgehod signaling and osteogenic differentiation in multipotent bone marrow stromal cells are inhibited by oxidative stress. J Cell Biochem 2010, 111:1199-1209.
95. Jemai H., Bouaziz M., Fki I., El Feki A., Sayadi S. Hypolipidimic and antioxidant activities of oleuropein and its hydrolysis derivative-rich extracts from Chemlali olive leaves. Chem Biol Interact 2008, 176:88-98.
96. Kasdallah-Grissa A., Nakbi A., Koubaa N., El-Fazaâ S., Gharbi N., Kamoun A., et al. Dietary virgin olive oil protects against lipid peroxidation and improves antioxidant status in the liver of rats chronically exposed to ethanol. Nutr Res 2008, 28:472-479.
97. Santiago-Mora R., Casado-Diaz A., De Castro M.D., Quesada-Gómez J.M. Oleuropein enhances osteoblastogenesis and inhibits adipogenesis: the effect of differentiation in stem cells derived from bone marrow. Osteoporos Int 2011, 22:675-684.
98. Bonnefont-Rousselot D., Bastard J.P., Jaudon M.C., Delattre J. Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab 2000, 26:163-176.
99. Botolin S., Faugere M.C., Malluche H., Orth M., Meyer R., McCabe L.R. Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice. Endocrinology 2005, 146:3622-3631.
100. Botolin S., McCabe L.R. Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss. J Cell Physiol 2006, 209:967-976.
101. Coe L.M., Lippner D., Perez G.I., McCabe L.R. Caspase-2 deficiency protects mice from diabetes-induced marrow adiposity. J Cell Biochem 2011, 112:2403-2411.
102. Slade J.M., Coe L.M., Meyer R.A., McCabe L.R. Human bone marrow adiposity is linked with serum lipids not T1-diabetes. J Diabet Complicat 2012, 26:1-9.
103. Zayzafoon M., Gathings W.E., McDonald J.M. Modeled microgravity inhibits osteogenic differentiation of human mesenchymal stem cells and increases adipogenesis. Endocrinology 2004, 145:2421-2432.
104. Ahdjoudj S., Lasmoles F., Holy X., Zerath E., Marie P.J. Transforming growth factor beta2 inhibits adipocyte differentiation induced by skeletal unloading in rat bone marrow stroma. J Bone Miner Res 2002, 17:668-677.
105. Wronski T.J., Morey-Holton E., Jee W.S. Skeletal alterations in rats during space flight. Adv Space Res 1981, 1:135-140.
106. Trudel G., Payne M., Mädler B., Ramachandran N., Lecompte M., Wade C., et al. Bone marrow fat accumulation after 60days of bed rest persisted 1year after activities were resumed along with hemopoietic stimulation: the Women International Space Simulation for Exploration study. J Appl Physiol 2009, 107:540-548.
107. Minaire P., Edouard C., Arlot M., Meunier P.J. Marrow changes in paraplegic patients. Calcif Tissue Int 1984, 36:338-340.
108. Luu Y.K., Capilla E., Rosen C.J., Gilsanz V., Pessin J.E., Judex S., et al. Mechanical stimulation of mesenchymal stem cell proliferation and differentiation promotes osteogenesis while preventing dietary-induced obesity. J Bone Miner Res 2009, 24:50-61.
109. Yuki A., Yotani K., Tamaki H., Kasuga N., Takekura H. Upregulation of osteogenic factors induced by high-impact jumping suppresses adipogenesis in marrow but not adipogenic transcription factors in rat tibiae. Eur J Appl Physiol 2010, 109:641-650.
110. David V., Martin A., Lafage-Proust M.H., Malaval L., Peyroche S., Jones D.B., et al. Mechanical loading down-regulates peroxisome proliferator-activated receptor gamma in bone marrow stromal cells and favors osteoblastogenesis at the expense of adipogenesis. Endocrinology 2007, 148:2553-2562.
111. Chen Y., Wang S., Bu S., Wang Y., Duan Y., Yang S. Treadmill training prevents bone loss by inhibition of PPARγ expression but not promoting of Runx2 expression in ovariectomized rats. Eur J Appl Physiol 2011, 111:1759-1767.
112. Colleran P.N., Wilkerson M.K., Bloomfield S.A., Suva L.J., Turner R.T., Delp M.D. Alterations in skeletal perfusion with simulated microgravity: a possible mechanism for bone remodeling. J Appl Physiol 2000, 89:1046-1054.
113. Ren H., Cao Y., Zhao Q., Li J., Zhou C., Liao L., et al. Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions. Biochem Biophys Res Commun 2006, 347:12-21.
114. Ontiveros C., Irwin R., Wiseman R.W., McCabe L.R. Hypoxia suppresses runx2 independent of modeled microgravity. J Cell Physiol 2004, 200:169-176.
115. Smith S.M., Zwart S.R., Block G., Rice B.L., Davis-Street J.E. The nutritional status of astronauts is altered after long-term space flight aboard the International Space Station. J Nutr 2005, 135:437-443.
116. Brookoff D., Weiss L. Adipocyte development and the loss of erythropoietic capacity in the bone marrow of mice after sustained hypertransfusion. Blood 1982, 60:1337-1344.
117. McManus P.M., Weiss L. Busulfan-induced chronic bone marrow failure: changes in cortical bone, marrow stromal cells, and adherent cell colonies. Blood 1984, 64:1036-1041.
118. Burkhardt R., Kettner G., Böhm W., Schmidmeier M., Schlag R., Frisch B., et al. Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study. Bone 1987, 8:157-164.
119. Lipetz J.S., Kirshblum S.C., O'Conner K.C., Voorman S.J., Johnston M.V. Anemia and serum protein deficiencies in patients with traumatic spinal cord injury. J Spinal Cord Med 1997, 20:335-340.
120. Islam A. Do bone marrow fat cells or their precursors have a pathogenic role in idiopathic aplastic anemia?. Med Hypotheses 1988, 25:209-217.
121. Payne M.W.C., Uhthoff H.K., Trudel G. Anemia of immobility: caused by adipocyte accumulation in bone marrow. Med Hypotheses 2007, 69:778-786.
122. Xu Y., Takahashi Y., Wang Y., Hama A., Nishio N., Muramatsu H., et al. Downregulation of GATA-2 and overexpression of adipogenic gene-PPARγ in mesenchymal stem cells from patients with aplastic anemia. Exp Hematol 2009, 37:1393-1399.
123. Tong Q., Tsai J., Hotamisligil G.S. GATA transcription factors and fat cell formation. Drug News Perspect 2003, 16:585-588.
124. Abella E., Feliu E., Granada I., Millá F., Oriol A., Ribera J.M., et al. Bone marrow changes in anorexia nervosa are correlated with the amount of weight loss and not with other clinical findings. Am J Clin Pathol 2002, 118:582-588.
125. Bredella M.A., Fazeli P.K., Miller K.K., Misra M., Torriani M., Thomas B.J., et al. Increased bone marrow fat in anorexia nervosa. J Clin Endocrinol Metab 2009, 94:2129-2136.
126. Ecklund K., Vajapeyam S., Feldman H.A., Buzney C.D., Mulkern R.V., Kleinman P.K., et al. Bone marrow changes in adolescent girls with anorexia nervosa. J Bone Miner Res 2010, 25:298-304.
127. Devlin M.J., Cloutier A.M., Thomas N.A., Panus D.A., Lotinun S., Pinz I., et al. Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. J Bone Miner Res 2010, 25:2078-2088.
128. Lawson E.A., Klibanski A. Endocrine abnormalities in anorexia nervosa. Nat Clin Pract 2008, 4:407-414.
129. Misra M., Klibanski A. Neuroendocrine consequences of anorexia nervosa in adolescents. Endocr Dev 2010, 17:197-214.
130. Fazeli P.K., Bredella M.A., Misra M., Meenaghan E., Rosen C.J., Clemmons D.R., et al. Preadipocyte factor-1 is associated with marrow adiposity and bone mineral density in women with anorexia nervosa. J Clin Endocrinol Metab 2010, 95:407-413.
131. Hamrick M.W., Della Fera M.A., Choi Y.H., Hartzell D., Pennington C., Baile C.A. Injections of leptin into rat ventromeidal hypothalamus increase adipocyte apoptosis in peripheral fat and in bone marrow. Cell Tissue Res 2007, 327:133-141.
132. Gevers E.F., Loveridge N., Robinson I.C. Bone marrow adipocytes: a neglected target tissue for growth hormone. Endocrinology 2002, 143:4065-4073.
133. Rosen C.J., Ackert-Bicknell C.L., Adamo M.L., Shultz K.L., Rubin J., Donahue L.R., et al. Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program. Bone 2004, 35:1046-1058.
134. Devlin M.J. Why does starvation make bones fat?. Am J Hum Biol 2011, 23:577-585.
135. Guo X., Yang W., Ni J., He M., Yang L. A role for suppressed bone formation favouring catch-up fat in the pathophysiology of catch-up growth after food restriction. Eur J Nutr 2011, 50:645-655.
136. Maes C., Kobayashi T., Selig M.K., Torrekens S., Roth S.I., Mackem S., et al. Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. Dev Cell 2010, 19:329-344.
137. Wilson A., Shehadeh L.A., Yu H., Webster K.A. Age-related molecular genetic changes of murine bone marrow mesenchymal stem cells. BMC Genomics 2010, 11:229.
138. Liu Y., Berendsen A.D., Jia S., Lotinun S., Baron R., Ferrara N., et al. Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J Clin Invest 2012, 122:3101-3113.
139. Brunner G., Gabrilove J., Rifkin D.B., Wilson E.L. Phospholipase C release of basic fibroblast growth factor from human bone marrow cultures as a biologically active complex with a phosphatidylinositol-anchored heparan sulfate proteoglycan. J Cell Biol 1991, 114:1275-1283.
140. Sabbieti M.G., Marchetti L., Abreu C., Montero A., Hand A.R., Raisz L.G., et al. Prostaglandins regulate the expression of fibroblast growth factor-2 in bone. Endocrinology 1999, 140:434-444.
141. Xiao L., Sobue T., Esliger A., Kronenberg M.S., Coffin J.D., Doetschman T., et al. Disruption of the Fgf2 gene activates the adipogenic and suppresses the osteogenic program in mesenchymal marrow stromal stem cells. Bone 2010, 47:360-370.
142. Itoh N., Ornitz D.M. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004, 20:563-569.
143. Reitman M.L. FGF21: a missing link in the biology of fasting. Cell Metab 2007, 5:405-407.
144. Wei W., Dutchak P.A., Wang X., Ding X., Wang X., Bookout A.L., et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proc Natl Acad Sci U S A 2012, 109:3143-3148.
145. Yamashita D., Yamaguchi T., Shimizu M., Nakata N., Hirose F., Osumi T. The transactivating function of peroxisome proliferator-activated receptor γ is negatively regulated by SUMO conjugation in the amino-terminal domain. Genes Cells 2004, 9:1017-1029.
146. Dutchak P.A., Katafuchi T., Bookout A.L., Choi J.H., Yu R.T., Mangelsdorf D.J., et al. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 2012, 148:556-567.
147. Chau M.D., Gao J., Yang Q., Wu Z., Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci U S A 2010, 107:12553-12558.
148. Hsu Y.H., Venners S.A., Terwedow H.A., Feng Y., Niu T., Li Z., et al. Relation of body composition, fat mass and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. Am J Clin Nutr 2006, 83:146-154.
149. Orozco P. Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight women. Eur J Epidemiol 2004, 19:1105-1112.
150. Cui L.H., Shin M.H., Chung E.K., Lee Y.H., Kweon S.S., Park K.S., et al. Association between bone mineral densities and serum lipid profiles of pre- and post-menopausal rural women in South Korea. Osteoporos Int 2005, 16:1975-1981.
151. Corwin R.L., Hartman T.J., Maczuga S.A., Graubard B.I. Dietary saturated fat intake is inversely associated with bone density in humans: analysis of NHANES III. J Nutr 2006, 136:159-165.
152. Michaëlsson K., Holmberg L., Mallmin H., Wolk A., Bergström R., Ljunghall S. Diet, bone mass, and osteocalcin: a cross-sectional study. Calcif Tissue Int 1995, 57:86-93.
153. Cooper C., Atkinson E.J., Hensrud D.D., Wahner H.W., O'Fallon W.M., Riggs B.L., et al. Dietary protein intake and bone mass in women. Calcif Tissue Int 1996, 58:320-325.
154. Bielohuby M., Matsuura M., Herbach N., Kienzle E., Slawik M., Hoeflich A., et al. Short term exposure to low-carbohydrate/high fat diets induces low bone mineral density and reduces bone formation in rats. J Bone Miner Res 2010, 25:275-284.
155. Parhami F., Jackson S.M., Tintut Y., Le V., Balucan J.P., Territo M., et al. Atherogenic diet and minimally oxidized low density lipoprotein inhibit ostegenic and promote adipogenic differentiation of marrow stromal cells. J Bone Miner Res 1999, 14:2067-2078.
156. Chen J.R., Lazarenko O.P., Wu X., Tong Y., Blackburn M.L., Shankar K., et al. Obesity reduces bone density associated with activation of PPARγ and suppression of Wnt/ß-catenin in rapidly growing male rats. PLoS One 2010, 5:e13704.
157. Chen J.R., Zhang J., Lazarenko O.P., Kang P., Blackburn M.L., Ronis M.J.J., et al. Inhibition of fetal bone development through epigenetic downregulation of HoxA10 in obese rats fed high-fat diet. FASEB 2012, 26:1131-1141.
158. Badilla F.C., Liendo R., Quintana A. Characterization of cocoa butter extracted from hybrid cultivars of Theobroma cacao L. Arch Latinoam Nutr 2000, 50:200-205.
159. Beadle J.B., Just D.E., Morgan R.E., Reiners R.A. Composition of corn oil. J Am Oil Chem Soc 1965, 42:90-95.
160. Rahman M.M., Halade G.V., Williams P.J., Fernandes G. t10c12-CLA maintains higher bone mineral density during aging by modulating osteoclastogenesis and bone marrow adiposity. J Cell Physiol 2011, 226:2406-2414.
161. Halade G.V., Rahman M.M., Williams P.J., Fernandes G. Combination of conjugated linoleic acid with fish oil prevents age-associated bone marrow adiposity in C57Bl/6J mice. J Nutr Biochem 2011, 22:459-469.
162. Casado-Diaz A., Santiago-Mora R., Dorado G., Quesada-Gómez J.M. The omega-6 arachidonic fatty acid, but not the omega-3 fatty acids, inhibits osteoblastogenesis and induces adipogenesis of human mesenchymal stem cells: potential implication in osteoporosis. Osteoporos Int 2013, 24:1647-1661.
163. Granlund L., Juvet L.K., Pedersen J.I., Nebb H.I. Trans10, cis12-conjugated linoleic acid prevents triacylglycerol accumulation in adipocytes by acting as a PPARgamma modulator. J Lipid Res 2003, 44:1441-1452.
164. Platt I.D., El-Sohemy A. Regulation of osteoblast and adipocyte differentiation from human mesenchymal stem cells by conjugated linoleic acid. J Nutr Biochem 2009, 20:956-964.
165. Kim J., Park Y., Lee S.H., Park Y. trans-10,cis-12 Conjugated linoleic acid promotes bone formation by inhibiting adipogenesis by peroxisome proliferator-activated receptor-γ-dependent mechanisms and by directly enhancing osteoblastogenesis from bone marrow mesenchymal stem cells. J Nutr Biochem 2013, 24:672-679.
166. Song C., Guo Z., Ma Q., Chen Z., Liu Z., Jia H., et al. Simvastatin induces osteoblastic differentiation and inhibits adipocytic differentiation in mouse bone marrow stromal cells. Biochem Biophys Res Commun 2003, 308:458-462.
167. Li X., Cui Q., Kao C., Wang G.J., Balian G. Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARgamma2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures. Bone 2003, 33:652-659.
168. Liu M., Wang K., Tang T., Dai K., Zhu Z. The effect of simvastatin on the differentiation of marrow stromal cells from aging rats. Pharmazie 2009, 64:43-48.
169. Slater E.E., MacDonald J.S. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative. Drugs 1988, 36:72-82.
170. Endo A., Tsujita Y., Kuroda M., Tanzawa K. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Biochem 1977, 77:31-36.
171. Ye Y., Nishi S.P., Manickavasagam S., Lin Y., Huang M.H., Perez-Polo J.R., et al. Activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2. Prostaglandins Other Lipid Mediat 2007, 84:43-53.
172. Yano M., Matsumura T., Senokuchi T., Ishii N., Murata Y., Taketa K., et al. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 2007, 100:1442-1451.
173. Nicholson A.C., Hajjar D.P., Zhou X., He W., Gotto A.M., Han J. Anti-adipogenic action of pitavastatin occurs through the coordinate regulation of PPARgamma and Pref-1 expression. Br J Pharmacol 2007, 151:807-815.
174. Majima T., Komatsu Y., Fukao A., Ninomiya K., Matsumara T., Nakao K. Short-term effects of atorvastatin on bone turnover in male patients with hypercholesterolemia. Endocr J 2007, 54:145-151.
175. Bone H.G., Kiel D.P., Lindsay R.S., Lewiecki E.M., Bolognese M.A., Leary E.T., et al. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab 2007, 92:4671-4677.
176. Yue J., Zhang X., Dong B., Yang M. Statins and bone health in post-menopausal women: a systematic review of randomized controlled trials. Menopause 2010, 17:1071-1079.
177. Lupattelli G., Scarponi A.M., Vaudo G., Siepi D., Roscini A.R., Gemelli F., et al. Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women. Metabolism 2004, 53:744-748.
178. Edwards C.J., Hart D.J., Spector T.D. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000, 355:2218-2219.
179. Uzzan B., Cohen R., Nicolas P., Cucherat M., Perrat G.Y. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 2007, 40:1581-1587.
180. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946-1949.
181. Maritz F.J., Conradie M.M., Hulley P.A., Gopal R., Hough S. Effects of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 2001, 21:1636-1641.
182. Chuengsamarn S., Rattanamongkoulgul S., Suwanwalaikorn S., Wattanasirichaigoon S., Kaufman L. Effects of statins vs non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidaemia. Bone 2010, 46:1011-1015.
183. Weivoda M.M., Hohl R.J. Geranylgeranyl pyrophosphate stimulates PPARγ expression and adipogenesis through the inhibition of osteoblast differentiation. Bone 2012, 50:467-476.
184. Benayahu D., Shur I., Ben Eliyahu S. Hormonal changes affect the bone and bone marrow cells in a rat model. J Cell Biochem 2000, 79:407-415.
185. Elbaz A., Rivas D., Duque G. Effect of estrogens on bone marrow adipogenesis and Sirt1 in aging C57BL/6J mice. Biogerontology 2009, 10:747-755.
186. Somjen D., Katzburg S., Kohen F., Gayer B., Posner G.H., Yoles I., et al. The effects of native and synthetic estrogenic compounds as well as vitamin D less-calcemic analogs on adipocytes content in rat bone marrow. J Endocrinol Invest 2001, 34:106-110.
187. Okazaki R., Inoue D., Shibata M., Saika M., Kido S., Ooka H., et al. Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta. Endocrinology 2002, 143:2349-2356.
188. Porcu M., Chiarugi A. The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol Sci 2005, 26:94-103.
189. Picard F., Kurtev M., Chung N., Topark-Ngarm A., Senawong T., Machado D.O., et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004, 429:771-776.
190. Backesjö C.M., Li Y., Lindgren U., Haldosen L.A. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J Bone Miner Res 2006, 21:993-1002.
191. Tseng P.C., Hou S.M., Chen R.J., Peng H.W., Hsieh C.F., Kuo M.L., et al. Resveratrol promotes osteogenesis of human mesenchymal stem cells by upregulating RUNX2 gene expression via the SIRT1/FOXO3A axis. J Bone Miner Res 2011, 26:2552-2563.
192. Goldberg D.M., Yan J., Ng E., Diamandis E.P., Karumanchiri A., Soleas G., et al. A global survey of trans-resveratrol concentrations in commercial wines. Am J Enol Vitic 1995, 46:1589-165.
193. Su J.L., Yang C.Y., Zhao M., Kuo M.L., Yen M.L. Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. J Biol Chem 2007, 282:19385-19398.
194. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.
195. Heim M., Frank O., Kampmann G., Sochocky N., Pennimpede T., Fuchs P., et al. The phytoestrogen genistein enhances osteogenesis and represses adipogenic differentiation of human primary bone marrow stromal cells. Endocrinology 2004, 145:848-859.
196. Lagari V.S., Levis S. Phytoestrogens and bone health. Curr Opin Endocrinol Diab Obes 2010, 17:546-553.
197. Shalhoub V., Conlon D., Tassinari M., Quinn C., Partridge N., Stein G.S., et al. Glucocorticoids promote development of the osteoblast phenotype by selectively modulating expression of cell growth and differentiation associated genes. J Cell Biochem 1992, 50:425-440.
198. Canalis E., Mazziotti G., Giustina A., Bilezikian J.P. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007, 18:1319-1328.
199. Rosen C.J., Klibanski A. Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med 2009, 122:409-414.
200. Zhou H., Mak W., Zheng Y., Dunstan C.R., Seibel M.J. Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through Wnt signaling. J Biol Chem 2008, 283:1936-1945.
201. Zhou H., Mak W., Kalak R., Street J., Fong-Yee C., Zheng Y., et al. Glucocorticoid-dependent Wnt signaling by mature osteoblasts is a key regulator of cranial skeletal development in mice. Development 2009, 136:427-436.
202. Ohnaka K., Tanabe M., Kawate H., Nawata H., Takayanagi R. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 2005, 329:177-181.
203. Pereira R.C., Delany A.M., Canalis E. Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone 2002, 30:685-691.
204. Idris A.I., Ralston S.H. Cannabinoids and bone: friend or foe?. Calcif Tissue Int 2010, 87:285-297.
205. Pertwee R.G., Ross R.A. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002, 66:101-121.
206. Ryberg E., Larsson N., Sjögren S., Hjorth S., Hermansson N.O., Leonova J., et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007, 152:1092-1101.
207. Idris A.I., Van't Hof R.J., Greig I.R., Ridge S.A., Baker D., Ross R.A., et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 2005, 11:774-779.
208. Ofek O., Karsak M., Leclerc N., Fogel M., Frenkel B., Wright K., et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A 2006, 103:696-701.
209. Idris A.I., Sophocleous A., Landao-Bassonga E., Canals M., Milligan G., Baker D., et al. Cannabinoid receptor type I protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. Cell Metab 2009, 10:139-147.
210. Whyte L.S., Ryberg E., Sims N.A., Ridge S.A., Mackie K., Greasley P.J., et al. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A 2009, 106:16511-16516.
211. Ko J.Y., Wu R.W., Kuo S.J., Chen M.W., Yeh D.W., Ke H.C., et al. Cannabinoid receptor 1 mediates glucocorticoid-induced bone loss in rats by perturbing bone mineral acquisition and marrow adipogenesis. Arthritis Rheum 2012, 64:1204-1214.
212. Einhorn D., Aroda V.R., Henry R.R. Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinol Metab Clin North Am 2004, 33:595-616.
213. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affintiy ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995, 270:12953-12956.
214. Okuno A., Tamemoto H., Tobe K., Ueki K., Mori Y., Iwamoto K., et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998, 101:1354-1361.
215. Hernandez A.V., Usmani A., Rajamanickam A., Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 2011, 11:115-128.
216. Woodcock J., Sharfstein J.M., Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med 2010, 363:1489-1491.
217. Roehr B. FDA committee urges tight restriction on rosiglitazone. BMJ 2010, 341:c3862.
218. Glintborg D., Andersen M., Hagen C., Heickendorff L., Hermann A.P. Association of pioglitazone treatment with reduced bone mineral density in obese premenopausal patients with polycystic ovarian syndrome: a randomized placebo-controlled trial. J Clin Endocrinol Metab 2008, 93:1696-1701.
219. Schwartz A.V., Sellmeyer D.E., Vittinghoff E., Palermo L., Lecka-Czernik B., Feingold K.R., et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006, 91:3349-3354.
220. Riche D.M., Travis King S. Bone loss and fracture risk associated with thiazolidinedione therapy. Pharmacotherapy 2010, 30:716-727.
221. Habib Z.A., Havstad S.L., Wells K., Divine G., Pladevall M., Williams L.K. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010, 95:592-600.
222. Aubert R.E., Herrera V., Chen W., Haffner S.M., Pendergrass M. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab 2010, 12:716-721.
223. Rzonca S.O., Suva L.J., Gaddy D., Montague D.C., Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004, 145:401-406.
224. Ali A.A., Weinstein R.S., Stewart S.A., Parfitt A.M., Manolagas S.C., Jilka R.L. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005, 146:1226-1235.
225. Grey A., Beckley V., Doyle A., Fenwick S., Horne A., Gamble G., et al. Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial. Eur J Endocrinol 2012, 166:1087-1091.
226. Watts N.B., Diab D.L. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010, 95:1555-1565.
227. Duque G., Rivas D. Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res 2007, 22:1603-1611.
228. Duque G., Li W., Adams M., Xu S., Phipps R. Effects of risedronate on bone marrow adipocytes in postmenopausal women. Osteoporos Int 2011, 22:1547-1553.
229. Li G.W., Chang S.X., Fan J.Z., Tian Y.N., Xu Z., He Y.M. Marrow adiposity recovery after early zoledronic acid treatment of glucocorticoid-induced bone loss in rabbits assessed by magnetic resonance spectroscopy. Bone 2013, 52:668-675.
230. Jin J., Wang L., Wang X., Lai P., Huang M., Jin D., et al. Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation. J Surg Res 2013, 180:E21-E29.
231. Zhang H.H., Huang J., Düvel K., Boback B., Wu S., Squillace R.M., et al. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One 2009, 4:e6189.
232. Kim J.E., Chen J. Regulation of peroxisome proliferator-activated receptor-γ activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 2004, 53:2748-2756.
233. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004, 350:459-468.
234. Marie P.J., Felsenberg D., Brandi M.L. How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporos Int 2011, 22:1659-1667.
235. Fournier C., Perrier A., Thomas M., Laroche N., Dumas V., Rattner A., et al. Reduction by strontium of the bone marrow adiposity in mice and repression of the adipogenic commitment of multipotent C3H10T1/2 cells. Bone 2012, 50:499-509.
236. Saidak Z., Haÿ E., Marty C., Barbara A., Marie P.J. Strontium ranelate rebalances bone marrow adipogenesis and osteblastogenesis in senescent osteopenic mice through NFATc/Maf and Wnt signaling. Aging Cell 2012, 11:467-474.
237. Takada I., Kouzmenko A.P., Kato S. Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol 2009, 5:442-447.
238. Fajas L., Egler V., Reiter R., Hansen J., Kristiansen K., Debril M.B., et al. The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation. Dev Cell 2002, 3:903-910.
239. Lecka-Czernik B., Moerman E.J., Grant D.F., Lehmann J.H., Manolagas S.C., Jilka R.L. Divergent effects of selective peroxisome proliferator-activated receptor-γ2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002, 143:2376-2384.
240. Higgins L.S., Mantzoros C.S. The development of INT131 as a selective PPARγ modulator: approach to a safer insulin sensitizer. PPAR Res 2008, 2008:936906.
241. Higgins L.S., DePaoli A.M. Selective peroxisome proliferator-activated receptor-γ modulation as a strategy for safer therapeutic PPARγ activation. Am J Clin Nutr 2010, 91:267S-272S. [Suppl.].
242. Lee D.H., Huang H., Choi K., Mantzoros C., Kim Y.-B. Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice. Am J Physiol Endocrinol Metab 2012, 302:E552-E560.